These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 10746590

  • 1. MS functional composite: relation to disease phenotype and disability strata.
    Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH.
    Neurology; 2000 Mar 28; 54(6):1233-9. PubMed ID: 10746590
    [Abstract] [Full Text] [Related]

  • 2. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S, Ormeci B, Idiman E.
    J Neurol Sci; 2005 May 15; 232(1-2):65-9. PubMed ID: 15850584
    [Abstract] [Full Text] [Related]

  • 3. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.
    Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F.
    Neurology; 2001 Jan 23; 56(2):215-9. PubMed ID: 11160958
    [Abstract] [Full Text] [Related]

  • 4. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S, Cagiran I, Ormeci B, Idiman E.
    J Neurol Sci; 2004 Mar 15; 218(1-2):3-7. PubMed ID: 14759626
    [Abstract] [Full Text] [Related]

  • 5. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 6. A study validating changes in the multiple sclerosis functional composite.
    Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH.
    Arch Neurol; 2002 Jan 20; 59(1):113-6. PubMed ID: 11790238
    [Abstract] [Full Text] [Related]

  • 7. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL, Zwemmer JN, Jelles B, Polman CH, Uitdehaag BM.
    Mult Scler; 2004 Oct 20; 10(5):569-74. PubMed ID: 15471375
    [Abstract] [Full Text] [Related]

  • 8. Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
    Hoogervorst EL, van Winsen LM, Eikelenboom MJ, Kalkers NF, Uitdehaag BM, Polman CH.
    Neurology; 2001 Apr 10; 56(7):934-7. PubMed ID: 11294932
    [Abstract] [Full Text] [Related]

  • 9. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2005 Mar 20; 58(3-4):113-8. PubMed ID: 15887414
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.
    Neurology; 2005 Mar 22; 64(6):992-5. PubMed ID: 15781814
    [Abstract] [Full Text] [Related]

  • 13. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
    Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS.
    Arch Neurol; 2000 Sep 25; 57(9):1319-24. PubMed ID: 10987899
    [Abstract] [Full Text] [Related]

  • 15. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
    Rudick RA, Cutter G, Reingold S.
    Mult Scler; 2002 Oct 25; 8(5):359-65. PubMed ID: 12356200
    [Abstract] [Full Text] [Related]

  • 16. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A.
    Mult Scler; 2004 Feb 25; 10(1):41-6. PubMed ID: 14760951
    [Abstract] [Full Text] [Related]

  • 17. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 25; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
    Brochet B, Deloire MS, Bonnet M, Salort-Campana E, Ouallet JC, Petry KG, Dousset V.
    Mult Scler; 2008 Nov 25; 14(9):1242-9. PubMed ID: 18653737
    [Abstract] [Full Text] [Related]

  • 20. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.
    Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E.
    Acta Neurol Scand; 2002 Mar 25; 105(3):164-8. PubMed ID: 11886358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.